Why Aphria Inc (TSX:APHA) Stock Rose 17% in August

Despite what was a pretty rough month for cannabis stocks, shares in Aphria Inc (TSX:APHA(NYSE:APHA), rose 17% in August. Find out what led to the stocks outperformance in this rapidly growing and exciting market.

Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Despite what’s been for the most part a rough patch for cannabis stocks, shares in Aphria Inc (TSX:APHA)(NYSE:APHA), Canada’s fourth largest licensed pot producer, rose 17% in August.

So what exactly led to APHA’s outperformance last month?

Let’s take a closer look and find out.

Aphria reported its fourth quarter and fiscal year-end earnings on August 1, and for the most part, the results were fairly encouraging.

Backed by strong growth in adult use, Aphria delivered impressive year-over-year numbers including revenues up 969% and gross profits that nearly doubled.

Growth was encouraging against its most recent third quarter results as well, including 75% net revenue growth and revenues for adult-use cannabis us 158% from the prior quarter.

Once again, the company continues to demonstrate that it can deliver results on a profitable basis as well, reporting net income of $15.8 million in the fourth quarter and adjusted EBITDA of $1.9 million for the quarter.

Those results compare favourably to the net loss of $108 million it had reported in the third quarter — and better than the $5 million in net losses reported in the fourth quarter one year ago.

Meanwhile, Aphria also closed a convertible note offering during the fourth quarter for proceeds of over US$335 million at a rate of 5.25% per year, and now has over $571 million of cash sitting on its books, including marketable investments.

That should set it up well to go after not only an expanding Canadian market, but also a rapidly growing international market for cannabis.

Also, while revenues per gram of cannabis sold did decline in the quarter, the company continues to go after new and untapped markets for the drug, including the announcement of a new CBD-based nutraceutical product line for the German market earlier this year.

With more than 200,000 plants already under cultivation for the current grow season, including the new expanded area of its Aphria One facility, management feels as though its now on track for annual production capacity of as much as 255,000 kilograms of the drug once all is said and done, including having received licenses for all of its facilities.

Foolish bottom line

In light of the fact that Aphria sold just 5,774 kilograms of cannabis during the fourth quarter those forecasted production estimates suggest that there’s still a long road ahead of this company before it truly gets to where it wants to go.

Yet it could prove to be a handsomely rewarding and exciting road for investors — provided management can trim some of its existing operating costs and return itself to the form that it was in when it became the first licensed pot producer to record a quarterly net profit.

Investors interested in the cannabis space will want to continue to watch this exciting company, which, despite a strong showing in August, still trades toward the bottom end of its trailing twelve-month price range.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »